Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker Launches IMPACT HD Mass Spec Providing Exceptional Proteomic Results

Published: Tuesday, June 11, 2013
Last Updated: Tuesday, June 11, 2013
Bookmark and Share
Bruker’s IMPACT HD sets a new scientific benchmark of well over 8000 protein identifications from whole-proteome analysis, a record-breaking insight into trace species in complex biological samples.

At the 61st ASMS conference, Bruker has introduced exciting new High-Definition capabilities in proteomics and biomarker research.

Patented low-noise Captivespray nanoBooster™ ionization coupled with record high-speed digitization Qq-TOF technology and steered by intelligent acquisition software defines complex samples more sharply than ever before.

The novel High-Definition accurate mass spectrometer, impact HD™ is the latest innovation in Bruker’s UHR-TOF product line.

It opens up enhanced analytical performance levels for all applications where trace analysis from complex, high-background matrices is challenge - such as biomarker research, identification of impurities or residue screening.

Thanks to extreme sensitivity broad mass-transfer ion optics and fastest ever 50Gbit/sec sampling technology a dynamic range of 5 orders of magnitude is achieved in one second of LC time.

Wide dynamic range at high speed is a prerequisite for high-resolution detection of low-abundance compounds in sharp UHPLC peaks and permits direct quantitation without re-run.

The HD performance is directed by unique intelligent self-optimizing Instant Expertise™ software. MSMS acquisition parameters are dynamically adapted precisely to the incident sample, independent of sample amount or complexity, translating directly into higher productivity and expert-caliber results first time.

Bruker also introduces the CaptiveSpray nanoBooster™ which complements all Bruker LCMS instruments for new performance levels in proteomics and glycoanalysis.

The new version of Bruker’s established CaptiveSpray source employs a novel dopant-enriched gas ionization environment to boost sensitivity, enhance charge state and reduce background noise to drive up protein ID rates significantly.

The ability to engineer enhanced charge state is especially beneficial on Bruker’s amazon ETD ion trap in the structural analysis of glycopeptides by ETD.

The features ensure IMPACT HD delivers the fastest time-to-success for customers across a broad applications portfolio ranging from small molecule identification and characterization; food, forensic and environmental screening, metabolomics, proteomics to antibody analysis.

“Dynamic range really means something in your proteomics analysis when it can genuinely be delivered at UHPLC speeds” commented Carsten Baessmann Head of Applications Development “today we’re showing in a proteomics sample more than 8440 proteins at a false discovery rate (FDR) of better than 1% are identified from a combined 2D LC separation experiment with a CaptiveSpray nanoBooster™ - impact HD system.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Awarded Fourth PeakForce Tapping Patent
AFM mode uniquely combines highest resolution imaging and material property mapping.
Thursday, July 24, 2014
Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker Celebrates Double Award Win at Pittcon 2012
The new GC-MS platform from Bruker Chemical and Applied Markets (CAM) Division – SCION TQ™ – picked up two prestigious awards at last week’s Pittcon in Orlando, Florida.
Tuesday, March 20, 2012
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!